Krystal Biotech Announces Second Quarter 2023 Financial Results and Operational Highlights
07 août 2023 07h00 HE
|
Krystal Biotech, Inc.
• VYJUVEK™ approved in the U.S. as the first and only topical redosable gene therapy for the treatment of dystrophic epidermolysis bullosa • 121 Patient Start Forms in the first six weeks of launch ...
Krystal Biotech Announces Pipeline Expansion into Oncology and FDA Acceptance of IND Application for Lead Oncology Candidate KB707
26 juil. 2023 16h14 HE
|
Krystal Biotech, Inc.
PITTSBURGH, July 26, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and...
Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of KB407 for the Treatment of Cystic Fibrosis
03 juil. 2023 07h00 HE
|
Krystal Biotech, Inc.
PITTSBURGH, July 03, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a biotechnology company focused on developing and commercializing genetic medicines for patients...
Krystal Biotech to Present at Upcoming Investor Conferences
05 juin 2023 07h00 HE
|
Krystal Biotech, Inc.
PITTSBURGH, June 05, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) a biotechnology company focused on developing and commercializing genetic medicines for patients...
Krystal Biotech Announces $160 Million Private Placement Equity Financing
22 mai 2023 07h00 HE
|
Krystal Biotech, Inc.
PITTSBURGH, May 22, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the Company) (NASDAQ: KRYS), a biotechnology company focused on developing and commercializing genetic medicines for patients with...
Krystal Biotech Receives FDA Approval for the First-Ever Redosable Gene Therapy, VYJUVEK™ (beremagene geperpavec-svdt) for the Treatment of Dystrophic Epidermolysis Bullosa
19 mai 2023 13h57 HE
|
Krystal Biotech, Inc.
Dystrophic Epidermolysis Bullosa (DEB) is a serious rare genetic disease that affects the skin and mucosal tissues and is caused by one or more mutations in the COL7A1 gene, resulting in lack of...
Krystal Biotech Announces First Quarter 2023 Financial Results and Operational Highlights
08 mai 2023 08h23 HE
|
Krystal Biotech, Inc.
PDUFA date of May 19, 2023Presented clinical data at ARVO on topical application of B-VEC to the eye to treat ocular complications in a patient with recessive dystrophic epidermolysis bullosa under...
Krystal Biotech Announces Clinical Data on Topical Application of B-VEC to the Eye to Treat Ocular Complications in a Patient with Dystrophic Epidermolysis Bullosa Under a Compassionate Use Program
24 avr. 2023 07h00 HE
|
Krystal Biotech, Inc.
Data presented at Association for Research in Vision and Ophthalmology Annual Meeting on April 23, 2023Topical application of B-VEC to the eye was well tolerated and patient showed significant...
Krystal Biotech to Present at Association for Research in Vision and Ophthalmology Annual Meeting
13 avr. 2023 07h00 HE
|
Krystal Biotech, Inc.
Clinical data on the compassionate use of B-VEC to treat a RDEB patient, with recurrent cicatrizing conjunctivitis that leads to conjunctival scarring, at the Bascom Palmer Eye Institute PITTSBURGH,...
Krystal Biotech Appoints Catherine Mazzacco to Board of Directors
06 mars 2023 07h00 HE
|
Krystal Biotech, Inc.
PITTSBURGH, March 06, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) a biotechnology company focused on developing and commercializing genetic medicines for patients...